Noble Financial Has Positive Estimate for ELDN Q2 Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Research analysts at Noble Financial raised their Q2 2026 earnings estimates for shares of Eledon Pharmaceuticals in a research note issued to investors on Friday, May 22nd. Noble Financial analyst R. Leboyer now forecasts that the company will earn ($0.19) per share for the quarter, up from their previous estimate of ($0.23). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.91) per share. Noble Financial also issued estimates for Eledon Pharmaceuticals’ Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.74) EPS.

A number of other equities research analysts have also recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Eledon Pharmaceuticals in a research report on Friday, March 27th. Wall Street Zen lowered Eledon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $9.67.

Eledon Pharmaceuticals Price Performance

NASDAQ:ELDN opened at $3.89 on Wednesday. The company has a 50 day moving average price of $3.42 and a 200-day moving average price of $2.49. Eledon Pharmaceuticals has a 1-year low of $1.35 and a 1-year high of $4.60. The firm has a market cap of $300.27 million, a price-to-earnings ratio of -5.05 and a beta of 0.94.

Eledon Pharmaceuticals (NASDAQ:ELDN) last issued its earnings results on Wednesday, May 13th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.11).

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ELDN. ADAR1 Capital Management LLC purchased a new stake in Eledon Pharmaceuticals during the 4th quarter worth approximately $2,751,000. Jefferies Financial Group Inc. purchased a new position in shares of Eledon Pharmaceuticals in the fourth quarter valued at approximately $2,387,000. Ensign Peak Advisors Inc boosted its stake in shares of Eledon Pharmaceuticals by 94.9% in the fourth quarter. Ensign Peak Advisors Inc now owns 2,464,919 shares of the company’s stock worth $3,722,000 after acquiring an additional 1,200,000 shares during the last quarter. AWM Investment Company Inc. acquired a new stake in shares of Eledon Pharmaceuticals in the fourth quarter worth approximately $1,661,000. Finally, Sphera Funds Management LTD. increased its position in shares of Eledon Pharmaceuticals by 97.4% during the fourth quarter. Sphera Funds Management LTD. now owns 2,132,131 shares of the company’s stock worth $3,220,000 after purchasing an additional 1,051,898 shares in the last quarter. Institutional investors and hedge funds own 56.77% of the company’s stock.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.

Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications.